Overview

Safety and Efficacy Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension

Status:
Completed

Trial end date:
2021-07-30

Target enrollment:

Participant gender:

Summary

A Phase 3 Study Comparing the Efficacy and Safety of Netarsudil Ophthalmic Solution 0.02% QD to Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% BID, for Treatment of Open-Angle Glaucoma or Ocular Hypertension Over A 4-Week Period.

Phase:

Phase 3

Details

Lead Sponsor:

Aerie Pharmaceuticals

Treatments:

Ophthalmic Solutions
Pharmaceutical Solutions